MGMT and central nervous system cancer: A HH/Gli1 inhibitor (GANT61) was found to sensitize U87MG and U251MG glioma cells to TMZ treatment by enhancing the DNA damage effect, suppressing MGMT expression and the Notch1 pathway [114].